Jennifer Lee

Dr. Jennifer Lee

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2024 in Transplantation Direct
Verified
Journal Article
Open access
JLJennifer Lee
Jennifer Lee
ARAndrea Do Rivero
Andrea Do Rivero
JRJ. Ross Renew
J. Ross Renew
ASAaron Spaulding
Aaron Spaulding
SBShalmali Borkar
Shalmali Borkar
BLBeth Ladlie
Beth Ladlie
Background.: Four-factor prothrombin complex concentrate (PCC) is a plasma product that contains factors II, VII, IX, X, protein C, and protein S. PCC can be used off-label to treat coagulopathy during orthotopic liver transplantation (OLT). However, its use comes with safety concerns regarding thrombosis. The purpose of our study is to determine the safety of PCC in OLT. Methods.: We conducted a retrospective cohort study of patients who received 4-factor PCC during OLT at our institution from January 1, 2018, to May 1, 2022, with a 1:1 match of 83 patients who received PCC and 83 patients who did not. We evaluated 30-d mortality, 1-y mortality, prevalence of thrombotic complications (portal vein thrombosis, deep venous thrombosis, myocardial infarction, and pulmonary embolus), and postoperative intensive care (ICU) length of stay (LOS). Results.: There was no significant difference in 30-d mortality (odds ratio [OR] 5; 95% confidence interval [CI], 0.58-42.8; P = 0.14), 1-y mortality (OR 3; 95% CI, 0.61-14.86; P = 0.18), or ICU LOS (OR –13.8; 95% CI, –39.2 to 11.6; P = 0.29). There was no increased incidence of thrombotic complications among patients receiving PCC 90 d after surgery, including portal vein thrombosis (OR 1.5; 95% CI, 0.42-5.32; P = 0.53), pulmonary embolus (OR 1; 95% CI, 0.14-7.1; P = 0.99), deep venous thrombosis (OR 0.67; 95% CI, 0.11-3.99; P = 0.66), and myocardial infarction (OR 1.67; 95% CI, 0.4-6.97; P = 0.48). Conclusions.: Although there was a statistically insignificant increase in mortality after PCC administration during OLT, we did not see a significant increase in perioperative complications, including thrombotic events and increased ICU LOS.

Verified
Journal Article
Open access
PDF file
JLJennifer Lee
Jennifer Lee
WAWesley L Allen
Wesley L Allen
CSCourtney Scott
Courtney Scott
SAStephen Aniskevich
Stephen Aniskevich
SPSher-Lu Pai
Sher-Lu Pai
Portopulmonary hypertension is a relatively common pathologic condition in patients with end-stage liver disease. Traditionally, severe pulmonary hypertension is regarded as a contraindication to liver transplantation (LT) due to a high perioperative mortality rate. Recently, extracorporeal membrane oxygenation (ECMO) has been utilized for intraoperative management of LT. As venoarterial (VA) ECMO may benefit certain high-risk LT patients by reducing the ventricular workload by the equivalent of the programmed flow rate, its usage requires multidisciplinary planning with considerations of the associated complications. We highlighted two cases at our single-center institution as examples of high-risk pulmonary hypertension patients undergoing LT on planned VA ECMO. These patients both survived the intraoperative period; however, they had drastically different postoperative outcomes, generating discussions on the importance of judicious patient selection. Since ECMO has removed the barrier of intraoperative survivability, the patient selection process may need to put weight on the patient’s potential for postoperative recovery and rehabilitation. Considerations on LT recipients undergoing preemptive ECMO need to expand from the ability of the patients to withstand the demands of the surgery during the immediate perioperative period to the long-term postoperative recovery course.

7 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GUGoyal Umadat
Goyal Umadat
JLJennifer Lee
Jennifer Lee
JRJordan C. Ray
Jordan C. Ray
RCRyan Chadha
Ryan Chadha
YMYaohua Ma
Yaohua Ma
SGShahyar Gharacholou
Shahyar Gharacholou
Background: Coronary artery disease (CAD) is common among liver transplantation (LT) candidates, yet whether pre-transplant percutaneous coronary intervention (PCI) improves post-LT outcomes remains uncertain. Methods: We conducted a single-center, Institutional Review Board-approved cohort study of adults undergoing LT from 2005 to 2025. Asymptomatic candidates with significant stenosis on invasive angiography were included; prior coronary artery bypass grafting was excluded. The primary endpoint was major adverse cardiovascular events (MACE: myocardial infarction [MI], stroke/transient ischemic attack, new systolic dysfunction, post-LT coronary revascularization, or all-cause death). Results: Among 111 patients (median age 65 years; 84% male), 66 (59%) underwent PCI and 45 (41%) were managed medically. Over a median 32 months of follow-up, 61 patients (55%) experienced MACE. Composite MACE did not differ between PCI and non-PCI groups (52% vs. 60%, p = 0.40; log-rank p = 0.59). Fine–Gray modeling showed no association of PCI with MACE; independent predictors were prior MI (HR 1.81, 95% CI 1.01–3.24) and pre-transplant dialysis (HR 2.13, 95% CI 1.07–4.24). Major bleeding occurred in 7%. Matched and era-stratified analyses were concordant. Conclusions: In asymptomatic LT candidates with angiographically severe CAD, pre-LT PCI was not associated with a lower incidence of post-LT MACE.

24 November 2025 in Liver Transplantation
Verified
Journal Article
Closed access
SPSher-Lu Pai
Sher-Lu Pai
JLJennifer Lee
Jennifer Lee
TSTaimur Sher
Taimur Sher
ZLZhuo Li
Zhuo Li
DPDana K. Perry
Dana K. Perry
SMShennen A. Mao
Shennen A. Mao

23 September 2023
Verified
Conference Paper
Closed access
GUGoyal Umadat
Goyal Umadat
JLJennifer Lee
Jennifer Lee
SPSurakit Pungpapong
Surakit Pungpapong
SGShahyar Gharacholou
Shahyar Gharacholou
**Introduction/Hypothesis:** The 2022 scientific statement from the American College of Cardiology/American Heart Association (ACC/AHA) and the 2 | POSTER